Bayesian Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bayesian Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,100	Closed	-$1.9M	–	1201
2022 Q1	$1.9M	Buy	+18,100	New	+$1.76M	0.28%	77
2021 Q1	–	Sell	-38,900	Closed	-$2.85M	–	751
2020 Q4	$2.85M	Buy	38,900 +16,400	+73%	+$1.22M	0.74%	23
2020 Q3	$1.75M	Buy	22,500 +3,100	+16%	+$213K	0.43%	52
2020 Q2	$1.08M	Sell	19,400 -7,000	-27%	-$299K	0.24%	118
2020 Q1	$782K	Buy	+26,400	New	+$893K	0.17%	178
2019 Q2	–	Sell	-29,600	Closed	-$782K	–	756
2019 Q1	$782K	Buy	+29,600	New	+$701K	0.15%	194

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bayesian Capital Management's HZNP Position: Q2 2022 in Review

Bayesian Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 18,100 shares — an estimated $1.9M sold.

Bayesian Capital Management first reported a position in HZNP in Q1 2019 and held it in 6 quarters. The position peaked at $2.85M in Q4 2020. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Bayesian Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Bayesian Capital Management sold 18,100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $1.9M.
Bayesian Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 6 quarters.
Bayesian Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.85M in Q4 2020.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.